For example, it has been reported that approximately 15% of individuals carrying p.R337H develop cancer by the age of 30, whereas patients who carry other mutations in the TP53 gene present a risk of 50% up to the age of 35 years [5, 10, 30]. This evidence concerns the gene TP53 and cancer.